Obstructive lung disease: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
mNo edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
* Bronchitis | * Bronchitis | ||
**[[Acute Bronchitis]] | **[[Acute Bronchitis]] | ||
**Chronic bronchitis (see below) | **Chronic bronchitis (see below) | ||
**[[Bronchiolitis]] | **[[Bronchiolitis]] | ||
* [[Chronic obstructive pulmonary disease]] (COPD) | * [[Chronic obstructive pulmonary disease]] (COPD) | ||
| Line 19: | Line 19: | ||
! heading !! Asthma!! COPD | ! heading !! Asthma!! COPD | ||
|- | |- | ||
| Long acting [[adrenergic beta-agonist]]s ||style="background:red"|may increase cardiovascular adverse effects, although this mainly be when used as monotherapy<ref name="pmid18646149">{{cite journal |author=Cates CJ, Cates MJ |title=Regular treatment with salmeterol for chronic asthma: serious adverse events |journal=Cochrane Database Syst Rev |volume= |issue=3 |pages=CD006363 |year=2008 |pmid=18646149 |doi=10.1002/14651858.CD006363.pub2 |url=http://dx.doi.org/10.1002/14651858.CD006363.pub2 |issn=}}</ref><ref name="pmid16424409">{{cite journal |author=Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM |title=The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol |journal=Chest |volume=129 |issue=1 |pages=15–26 |year=2006 |month=January |pmid=16424409 |doi=10.1378/chest.129.1.15 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=16424409 |issn=}}</ref> || style="background:lightgreen"|may reduce death<ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref> and slow progression of airway obstruction, especially when combined with inhaled [[glucocorticoid]]<ref name="pmid18511702">{{cite journal |author=Celli BR, Thomas NE, Anderson JA, ''et al'' |title=Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study |journal=Am. J. Respir. Crit. Care Med. |volume=178 |issue=4 |pages=332–8 |year=2008 |month=August |pmid=18511702 |doi=10.1164/rccm.200712-1869OC |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=18511702 |issn=}}</ref>. | | Long acting [[adrenergic beta-agonist]]s ||style="background:red"|may increase cardiovascular adverse effects, although this mainly be when used as ''monotherapy''<ref name="pmid18646149">{{cite journal |author=Cates CJ, Cates MJ |title=Regular treatment with salmeterol for chronic asthma: serious adverse events |journal=Cochrane Database Syst Rev |volume= |issue=3 |pages=CD006363 |year=2008 |pmid=18646149 |doi=10.1002/14651858.CD006363.pub2 |url=http://dx.doi.org/10.1002/14651858.CD006363.pub2 |issn=}}</ref><ref name="pmid16424409">{{cite journal |author=Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM |title=The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol |journal=Chest |volume=129 |issue=1 |pages=15–26 |year=2006 |month=January |pmid=16424409 |doi=10.1378/chest.129.1.15 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=16424409 |issn=}}</ref> || style="background:lightgreen"|may reduce death<ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref> and slow progression of airway obstruction, especially when combined with inhaled [[glucocorticoid]]<ref name="pmid18511702">{{cite journal |author=Celli BR, Thomas NE, Anderson JA, ''et al'' |title=Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study |journal=Am. J. Respir. Crit. Care Med. |volume=178 |issue=4 |pages=332–8 |year=2008 |month=August |pmid=18511702 |doi=10.1164/rccm.200712-1869OC |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=18511702 |issn=}}</ref>. | ||
|- | |- | ||
| [[Cholinergic antagonist]]s ||Possibly beneficial<ref name="pmid15266477">{{cite journal |author=Westby M, Benson M, Gibson P |title=Anticholinergic agents for chronic asthma in adults |journal=Cochrane Database Syst Rev |volume= |issue=3 |pages=CD003269 |year=2004 |pmid=15266477 |doi=10.1002/14651858.CD003269.pub2 |url=http://dx.doi.org/10.1002/14651858.CD003269.pub2 |issn=}}</ref><ref name="pmid10381989">{{cite journal |author=Stoodley RG, Aaron SD, Dales RE |title=The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials |journal=Ann Emerg Med |volume=34 |issue=1 |pages=8–18 |year=1999 |month=July |pmid=10381989 |doi= |url= |issn=}}</ref> || style="background:red"|may increase cardiovascular adverse effects<ref name="pmid18794557">{{cite journal |author=Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB |title=Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease |journal=Ann. Intern. Med. |volume=149 |issue=6 |pages=380–90 |year=2008 |month=September |pmid=18794557 |doi= |url=http://www.annals.org/cgi/content/full/149/6/380 |issn=}}</ref><ref>Sonal Singh, Yoon K. Loke, and Curt D. Furberg (2008). [http://jama.ama-assn.org/cgi/content/full/300/12/1439 Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis]. JAMA: The Journal of the American Medical Association 300 (12), 1439-50 (24 Sep 2008) {{doi|10.1001/jama.300.12.1439}}</ref> | | [[Cholinergic antagonist]]s ||Possibly beneficial<ref name="pmid15266477">{{cite journal |author=Westby M, Benson M, Gibson P |title=Anticholinergic agents for chronic asthma in adults |journal=Cochrane Database Syst Rev |volume= |issue=3 |pages=CD003269 |year=2004 |pmid=15266477 |doi=10.1002/14651858.CD003269.pub2 |url=http://dx.doi.org/10.1002/14651858.CD003269.pub2 |issn=}}</ref><ref name="pmid10381989">{{cite journal |author=Stoodley RG, Aaron SD, Dales RE |title=The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials |journal=Ann Emerg Med |volume=34 |issue=1 |pages=8–18 |year=1999 |month=July |pmid=10381989 |doi= |url= |issn=}}</ref> || style="background:red"|may increase cardiovascular adverse effects<ref name="pmid18794557">{{cite journal |author=Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB |title=Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease |journal=Ann. Intern. Med. |volume=149 |issue=6 |pages=380–90 |year=2008 |month=September |pmid=18794557 |doi= |url=http://www.annals.org/cgi/content/full/149/6/380 |issn=}}</ref><ref>Sonal Singh, Yoon K. Loke, and Curt D. Furberg (2008). [http://jama.ama-assn.org/cgi/content/full/300/12/1439 Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis]. JAMA: The Journal of the American Medical Association 300 (12), 1439-50 (24 Sep 2008) {{doi|10.1001/jama.300.12.1439}}</ref> | ||
| Line 27: | Line 27: | ||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 17:01, 27 September 2024
In medicine, obstructive lung disease is "any disorder marked by persistent obstruction of bronchial air flow."[1]
Classification
- Asthma
- Bronchitis
- Acute Bronchitis
- Chronic bronchitis (see below)
- Bronchiolitis
- Chronic obstructive pulmonary disease (COPD)
- Chronic bronchitis is a "subcategory of [[chronic obstructive pulmonary] disease]]. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis."[2]
- Emphysema is a "subcategory of [[chronic obstructive pulmonary] disease]]. The disease is characterized by anatomic alterations of the lungs, such as the enlargement of airspaces and destruction of alveolar walls."[3]
Treatment
Among the chronic varieties of obstructive lung disease, asthma and chronic obstructive pulmonary disease, is very important for determining treatment.
| heading | Asthma | COPD |
|---|---|---|
| Long acting adrenergic beta-agonists | may increase cardiovascular adverse effects, although this mainly be when used as monotherapy[4][5] | may reduce death[6] and slow progression of airway obstruction, especially when combined with inhaled glucocorticoid[7]. |
| Cholinergic antagonists | Possibly beneficial[8][9] | may increase cardiovascular adverse effects[10][11] |
| Inhaled glucocorticoids | beneficial[12] | as a monotherapy, may increase the risk of pneumonia.[6] |
References
- ↑ Anonymous (2024), Obstructive lung disease (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Chronic bronchitis (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Pulmonary emphysema (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Cates CJ, Cates MJ (2008). "Regular treatment with salmeterol for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006363. DOI:10.1002/14651858.CD006363.pub2. PMID 18646149. Research Blogging.
- ↑ Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (January 2006). "The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol". Chest 129 (1): 15–26. DOI:10.1378/chest.129.1.15. PMID 16424409. Research Blogging.
- ↑ 6.0 6.1 Calverley PM, Anderson JA, Celli B, et al (February 2007). "Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease". N. Engl. J. Med. 356 (8): 775–89. DOI:10.1056/NEJMoa063070. PMID 17314337. Research Blogging.
- ↑ Celli BR, Thomas NE, Anderson JA, et al (August 2008). "Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study". Am. J. Respir. Crit. Care Med. 178 (4): 332–8. DOI:10.1164/rccm.200712-1869OC. PMID 18511702. Research Blogging.
- ↑ Westby M, Benson M, Gibson P (2004). "Anticholinergic agents for chronic asthma in adults". Cochrane Database Syst Rev (3): CD003269. DOI:10.1002/14651858.CD003269.pub2. PMID 15266477. Research Blogging.
- ↑ Stoodley RG, Aaron SD, Dales RE (July 1999). "The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials". Ann Emerg Med 34 (1): 8–18. PMID 10381989. [e]
- ↑ Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB (September 2008). "Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease". Ann. Intern. Med. 149 (6): 380–90. PMID 18794557. [e]
- ↑ Sonal Singh, Yoon K. Loke, and Curt D. Furberg (2008). Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association 300 (12), 1439-50 (24 Sep 2008) DOI:10.1001/jama.300.12.1439
- ↑ Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates C (2005). "Fluticasone versus placebo for chronic asthma in adults and children". Cochrane Database Syst Rev (4): CD003135. DOI:10.1002/14651858.CD003135.pub3. PMID 16235315. Research Blogging.